About Smad nuclear-interacting protein 1
Smad nuclear-interacting protein 1 (SNIP1) is a protein
from Homo sapiens identified by UniProt accession
Q8TAD8, 396 residues long.
MolForge cross-references it against 0 known binders and
86 disease associations.
Target properties
| Protein name | Smad nuclear-interacting protein 1 |
| UniProt accession | Q8TAD8 |
| Gene | SNIP1 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (86)
Diseases linked to this target (Open Targets).
- Christianson syndrome · score 0.63
- neurodegenerative disease · score 0.52
- Rolandic epilepsy · score 0.33
- childhood epilepsy with centrotemporal spikes · score 0.33
- intraocular pressure measurement · score 0.12
- FEV/FVC ratio · score 0.09
- forced expiratory volume · score 0.09
- malignant epithelial tumor of ovary · score 0.09
- cardiac hypertrophy · score 0.07
- body mass index · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TAD8-F1 | alphafold | PREDICTED | 66.06 | — |
Amino-acid sequence (396 residues)
MKAVKSERER GSRRRHRDGD VVLPAGVVVK QERLSPEVAP PAHRRPDHSG GSPSPPTSEP ARSGHRGNRA RGVSRSPPKK KNKASGRRSK SPRSKRNRSP HHSTVKVKQE REDHPRRGRE DRQHREPSEQ EHRRARNSDR DRHRGHSHQR RTSNERPGSG QGQGRDRDTQ NLQAQEEERE FYNARRREHR QRNDVGGGGS ESQELVPRPG GNNKEKEVPA KEKPSFELSG ALLEDTNTFR GVVIKYSEPP EARIPKKRWR LYPFKNDEVL PVMYIHRQSA YLLGRHRRIA DIPIDHPSCS KQHAVFQYRL VEYTRADGTV GRRVKPYIID LGSGNGTFLN NKRIEPQRYY ELKEKDVLKF GFSSREYVLL HESSDTSEID RKDDEDEEEE EEVSDS
Explore Smad nuclear-interacting protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets